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Abstract
The systemic host defence mechanisms, especially innate immunity, in venous leg ulcer
patients are poorly investigated. The aim of the current study was to measure Candida
albicans killing activity and gene expressions of pro- and anti-inflammatory cytokines
and innate immune response regulators, TAM receptors and ligands of peripheral blood
mononuclear cells separated from 69 venous leg ulcer patients and 42 control probands.
Leg ulcer patients were stratified into responder and non-responder groups on the basis
of wound healing properties. No statistical differences were found in Candida killing
among controls, responders and non-responders. Circulating bloodmononuclear cells of
patients overexpress pro-inflammatory (IL-1α, TNFα, CXCL-8) and anti-inflammatory
(IL-10) cytokines as well as TAM receptors (Tyro, Axl, MerTK) and their ligands
Gas6 and Protein S compared with those of control individuals. IL-1α is notably
overexpressed in venous leg ulcer treatment non-responders; in contrast, Axl gene
expression is robustly stronger among responders. These markers may be considered
as candidates for the prediction of treatment response among venous leg ulcer patients.
Introduction
High ambulatory venous pressure is the hallmark of chronic
venous insufficiency (1,2) postulating increased iron deposition
(3). There is a growing body of evidence that persistent venous
congestion is probably insufficient to produce venous-origin
chronic wounds. Tissue damage evokes coagulation cas-
cade and numerous substances in the injured area act as
general leukocyte- and macrophage-attractant mediators
(1,2,4). Failures in defence mechanism and haemostasis seem
to be the coplayers of venous leg ulcer (VLU) formation
causing a cascade of inflammation and tissue demolition
with a concomitant microbial colonisation. The abundant
complexity of chronic wound healing sheds light on the
significance of innate and adaptive immune responses, espe-
cially in the phases of inflammation and proliferation. Innate
Key Messages
• venous leg ulcer (VLU) is characterised by a complex
immune cascade
• VLU is locked in non-resolving inflammation
• Staphylococcus aureus and Pseudomonas aeruginosa are
the dominant microbes of VLU
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• Candida albicans killing, the functional measure of
antimicrobial activity, is less effective among VLU
patients compared with control probands; however, it
does not reach statistical significance
• circulating blood mononuclear cells of VLU patients
overexpress pro-inflammatory (IL-1α, TNFα, CXCL-8)
and anti-inflammatory (IL-10) cytokines compared with
control probands
• TAM receptors (Tyro, Axl, MerTK) and their ligands
Gas6 and Protein S exhibit higher expression pattern in
VLU patients compared with control individuals
• Axl gene expression is significantly higher among VLU
patients having sufficient response to standard wound
care; in contrast, IL-1α is robustly overexpressed in VLU
non-respondersAQ3
immunity provides the first defence line against invaders
and tissue damage particles encompassing epithelial barriers,
phagocytes [macrophages, polymorphonuclear leukocytes
(PMNLs)], natural killer cells (NK cells), complement sys-
tem proteins and the iron homeostasis regulator, innate
immunity component lactoferrin (1–3,5–7). Bacterial coloni-
sation amplifies inflammatory response via interaction with
effector immune cells, cytokines and extracellular matrix com-
ponents. Bacteria are known to potentially modulate the local
immune response and drive the pro-inflammatory phenotype
of the wound and are supposed to influence the systemic
immune surveillance (8). Collaborating cells use a specific
pattern of cytokine and chemokine array. Upregulation of
antimicrobial peptides and inflammatory cytokines (e.g. IL-1α,
TNFα, CXCL-8, IL-10) highlights the persistent inflammation
in chronic wound (1,2,6–11). PMNLs clean the wounded
area after which the circulating monocytes enter the wound
and mature into tissue macrophages and dendritic cells. NK
cells are also activated by macrophages to kill intracellular
microbes (1,2). Among these components, macrophages have a
fundamental role in the immunological phenomena that occur
during wound healing processes (12,13). Basically, chronic
non-healing wounds are locked in non-resolving inflammation
(6,7,10,14). It might be due to two distinct reasons: (i) erad-
ication of microbes is insufficient, and thus a weak immune
response could result in granulomatous-like reactions (15) and
(ii) on the contrary, exaggerated immune response also does
not let wounds go towards the proliferation phase. Dysregu-
lation might play a pivotal role in each mechanism. One of
the key features in non-healing wounds appeared to be the
constant stimulation of innate immune response (10). Besides
effector mechanisms, regulation is assumed to play a crucial
role in tailoring innate immune responses. The TAM (Tyro,
Axl, MerTK) family of receptor tyrosine kinases and their
ligands Gas6 and Protein S (ProS) are a group of proteins
with innate immune regulation function (16–20). Although
it is known that they promote apoptosis and phagocytosis,
NK-cell maturation, platelet aggregation, angiogenesis and
also downregulate inflammation (16–22), their role in chronic
wound healing has not yet been investigated.
Chronic wound healing studies are mostly devoted to local
mechanisms, but we assumed that VLU patients have sys-
temic host defence alterations. According to our working
hypothesis, peripheral blood mononuclear cells (PBMCs) from
patients with VLUs could possess reduced Candida albicans
killing (23) ability and altered gene expression pattern of pro-
and anti-inflammatory cytokines/chemokines, TAM receptor
family members and their ligands. To test this hypothesis,
we (i) quantified the innate immune function of circulating
PBMCs with in vitro measurement of Candida killing activity
as a general assessment for function and (ii) determined the
gene expression of immune effector molecules IL-1α, TNFα,
CXCL-8 and IL-10 and receptors Tyro3, Axl and MerTK as
well as their ligands Gas6 and ProS in probands with and
without VLU. Finally, we sought to examine whether respon-
der and non-responder probands to VLU therapy could be
distinguishable according to Candida killing efficacy, gene
expression or microbial colonisation patterns.
Materials and methods
Patients
A total of 69 patients with VLU [33 females and 36 males with
a mean age of 66⋅71 years (range 23–90 years)] and another
42 age- and gender-matched control probands [25 females
and 17 males with a mean age of 60⋅81 years (range 25–86
years)] without VLU were recruited following the approval
of the Local Research Ethical Committee of the University
of Szeged and a written informed consent at the Wound Care
Outpatient Unit of the Department of Dermatology and Aller-
gology, University of Szeged. Exclusion criteria comprised
age <18 years, immunocompromised status, immunosuppres-
sant therapy, antibiotic therapy, diabetes mellitus, osteomyeli-
tis, exposed bone in the ulcer bed, ankle-brachial pressure index
<0⋅8 and clinical signs of severe inflammation (e.g. erysipelas,
cellulitis).
Among the VLU patients, duplex ultrasound findings dis-
closed superficial vein incompetence in 22 cases (31⋅88%),
perforator incompetence in 15 cases (21⋅73%) and combined
(superficial+ perforator) in 32 cases (46⋅37%). Deep venous
reflux was detected in 19 cases (27⋅53%). Mean ulcer area was
23⋅2 cm2 (2⋅3–200⋅85 cm2).
Eligible patients underwent blood sampling for laboratory
examinations (HbA1c, C-reactive protein, white blood cell,
kidney and liver function, uric acid, total protein, albumin,
iron) and wound bed swabs were collected for microbiological
culture.
The VLU patients were further stratified on the basis of
their responsiveness to the applied wound care procedure (24).
Patients with an ulcer area reduction≥ 20% in a 4-week period
became responders (n= 25) and those with slower wound heal-
ing were enrolled to non-responder group (n= 44).
Microbiological procedure
Between undressing and cleansing, the ulcer bed was swabbed
using a broad Z-stroke technique with a sterile cotton bud that
was placed immediately in sterile transport medium. Tubes
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
2 © 2015 Medicalhelplines.com Inc and John Wiley & Sons Ltd
K. Filkor et al. Innate immune response regulation in venous leg ulcer patients
with transport media were suspended in 1ml reduced brain
heart infusion (BHI; pH 7⋅2; Oxoid) broth and after gentle
dispersion, these suspensions were plated immediately on
selective and non-selective media. Samples were inoculated
onto 5% sheep blood agar, chocolate agar, eosin methylene
blue agar (bioMérieux) and Sabouraud agar plates. Endo agarAQ4
(bioMérieux) was used for selective isolation of Enterobacter
species. These plates were incubated in 10% CO2 atmosphere
and normal atmosphere for 24 hours at 37∘C; Sabouraud
plates were incubated for another 5 days at room temperature.
Columbia agar base supplemented with 5% blood, haemin and
vitamin K1 was used to isolate anaerobes and to determine the
colony-forming units (CFUs) in the case of tissue samples.AQ5
Because of the possible presence of black-pigmented anaerobic
gram-negative bacilli (Prevotella spp., Porphyromonas spp.)
kanamycin-vancomycin-laked blood (KVLB) agar (Oxoid)
was applied. Cultures were incubated for 5 days in an anaero-
bic cabinet (90% N2, 5% H2 and 5% CO2) (Bactron Sheldon
Man) at 37∘C. Species- or genus-level identifications were
achieved by traditional biochemical methods, ATB/VITEK
(bioMérieux) kits and/or MALDI-TOF (Bruker Daltonik)
method.
PBMC isolation from blood samples
Citrated blood samples (20ml) drawn from cubital veins were
collected from age- and gender-matched probands with and
without VLU. PMBCs were separated using Ficoll-Paque Plus
(GE Healthcare) density gradient centrifugation as described
previously (25). For this, twofold dilutions were made from
blood samples with ice-cold phosphate-buffered saline (PBS)
(Gibco) and layered on Ficoll-Paque Plus. Samples were cen-
trifuged for 30minutes at 700 rpm and the PBMC layersAQ6
were collected and washed with PBS. About 25% of the iso-
lated PBMCs were suspended in RPMI-1640 medium (Gibco)
supplemented with 10% heat-inactivated foetal bovine serum
(FBS, Gibco) and 1% penicillin-streptomycin solution (Gibco)
for killing experiments.
C. albicans killing assay
C. albicans growth conditions: C. albicans SC5314 was inoc-
ulated into 2ml of YPD [0⋅5% m/V yeast extract, 1% (m/V)
peptone and 1% (m/V) glucose) supplemented with 100 U/ml
penicillin–streptomycin solution and was incubated at 37∘C in
an orbital shaker at 200 rpm.
Candida killing assay was performed in 96-well plates.
A total of 50 000 PBMCs in 100 μl of RPMI-1640 media
were plated per well immediately after isolation. C. albi-
cans culture was washed two times with sterile PBS (cen-
trifugation at 2500 g, 5minutes) and diluted in RPMI-1640
to 2⋅5 * 106/ml, and 100 μl of this suspension was added
to PBMCs and to wells containing only 100 μl RPMI-1640
media as control. The cells were incubated for 3 hours at
37∘C, 100% relative humidity and 5% CO2 tension. PBMCs
were then disrupted by forcing them through a 27G nee-
dle with a sterile syringe for five times. The lysate was
diluted in sterile PBS, plated onto YPD supplemented with
penicillin–streptomycin and incubated for 2 days at 30∘C.
Table 1 FAM- or VIC-conjugated commercially available TaqMan assays
used in QRT-PCR studies
Target name Assay number
18S rRNA (FAM conjugated) Hs99999901
IL-10 (FAM conjugated) Hs99999035_m1
MerTK (VIC conjugated) Hs01031979_m1
Tyro3 (VIC conjugated) Hs00170723_m1
Axl (FAM conjugated) Hs00242357
CXCL8 (VIC conjugated) Hs00174103_m1
TNFα (FAM conjugated) Hs00174128_m1
Gas6 (FAM conjugated) Hs00181321_m1
ProS (VIC conjugated) Hs00165590_m1
FAM,; QRT-PCR, quantitative reverse transcriptase polymerase chain
reaction; VIC,.
Colonies were then counted and the killing efficiency was cal-
culated by using the following formula: %killing = [(Average
CFUcontrol −Average CFUcoincubated)/Average CFU control] * 100.
Quantitative reverse transcriptase polymerase chain
reaction (QRT-PCR)
Total RNA extraction, cDNA synthesis andQRT-PCRmeasure-
ments were performed as described previously (26). Briefly,
total RNA was extracted from PBMCs by using RNeasy Plus
Mini Kit (Qiagen) according to the manufacturer’s instructions.
The quality and the quantity of extracted RNAs were deter-
mined by NanoDrop (Thermo Scientific), Qubit (Life Tech-
nologies) and Bioanalyzer (Agilent) measurements. cDNA was
synthesised from 100 ng of total RNA by using High Capacity
RNA to cDNA Kit (Life Technologies) according to the manu-
facturer’s instructions. The relative abundance of Axl, Tyro3,
CXCL8, Gas6, IL-1α, IL-10, MerTK, ProS and TNFα was
determined by QRT-PCR by using StepOne Plus Real-Time
PCR System (Life Technologies). Reactions were performed
by using TaqMan Gene Expression Master Mix (Life Tech-
nologies) for commercially available FAM- or VIC-conjugated
TaqMan probes (Life Technologies) in multiple reactions;
TaqMan assay IDs are listed in Table 1. As controls, reac-
tion mixtures without cDNA were used. All of the experi-
ments were performed in two technical replicates. The ratio
of each mRNA relative to the 18S rRNA was calculated using
the 2−ΔΔCt method.
Statistical analysis
Data show average± standard error of the mean. The signif-
icance of difference between sets of data was determined by
one-way ANOVA following Neuman–Keuls post hoc test, or
Student’s paired t-test (comparison of laboratory values), using
GraphPad Prism forWindows. A probability (P) value of<0⋅05
was considered significant.
Sample size calculations, performed with Statistica 9.1 (Stat-
Soft), showed that at least four probands in the VLU and at least
four probands in the control group were needed to be included
if suspected unstimulated Candida killing activity is 10% in the
VLU and 20% in the control groups with a power of 80% and an
𝛼 error of 0⋅05 (one-sided). Importantly, our group sizes greatly
exceeded the calculated ones.
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Figure 1 Pseudomonas aeruginosa and Staphylo-
coccus aureus are characteristic for swab cultures
obtained from non-responders. Althoughmoremicro-
bial species are present in swab cultures obtained
from responders as compared with non-responders
(19 versus 8), the amount of isolated P. aeruginosa and
Staphylococcus aureus was elevated as compared
with that in responders (22% and 39% versus 16%
and 19%, respectively).
Results
Patients with VLU have altered laboratory values
At first, we determined and compared the laboratory values
of all 111 persons involved in the study. We found significant
differences in the following laboratory values between the
patient and control groups: leukocytosis was found in 45⋅45%
of patients and 21⋅95% of control probands (P= 0⋅022), low
haemoglobin value was observed in 48⋅52% of patients and
19⋅51% among control persons (P= 0⋅039), high urea value
was detected in 13⋅23% of affected and in 0% of unaffected
persons (P= 0⋅013) (data not shown).
Microbial composition of VLUs
The most common microorganisms involved in VLU microbial
burden were Staphylococcus aureus (18%), Pseudomonas
aeruginosa (17%) and Escherichia coli (9%) (data not
shown). Interestingly, there is a notable shift in the pro-
portion of microbes after stratification into responders and
non-responders (Figure 1). Patients with recalcitrant ulcers
showed predominantly S. aureus (39%) and P. aeruginosa
(22%). In contrast, responders showed a more balanced com-
position of detected infectious agents; however, P. aeruginosa
(16%) and S. aureus (13%) remained the predominant species
(Figure 1).
PBMCs from patients with VLU exhibit normal Candida
killing activity
In order to determine if PBMCs from VLU patients exhibit
altered functional properties, we performed in vitro Candida
killing assay. Even though PBMCs of patients with VLU
had lower Candida killing activity, there were no significant
differences among control, responder and non-responder
patient groups (Figure 2).
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Figure 2 Candida albicans killing by circulating peripheral bloodmononu-
clear cells. Killing efﬁciencies were evaluated in responder and
non-responder venous leg ulcer patients and control persons. No signif-
icant differences were detected in the percentage of dead yeasts in the
comparative study. Bars showmeans ± SEM (one-way ANOVA following
Neuman–Keuls post hoc test; P ≤0⋅05).
Altered gene expression pattern of pro-
and anti-inﬂammatory mediators in responders
and non-responders
The outcome of the immune response depends, in part, on
the nature of the pro-inflammatory proteins released locally
by the immune cells. Pro- and anti-inflammatory cytokines
and chemokines, such as IL-1α, TNFα, IL-10 and CXCL8,
secreted by various cell types play a fundamental role in
attracting neutrophils and T cells to the site of skin infection.
Therefore, we determined the gene expression pattern of the
above-mentioned molecules in PBMCs from control probands
and patients with VLU. QRT-PCR results showed that the
expression of all four genes was significantly higher in patients
with VLU in comparison to control probands (Figure 3A).
Moreover, we detected marked differences when the expres-
sion of the above-mentioned four genes from PBMCs was
compared between responder and non-responder VLU patients.
Pro-inflammatory mediators IL-1α and CXCL-8 showed sig-
nificantly increased expression in non-responders, with TNFα
having similar profile although statistically non-significant
(P= 0⋅757) (Figure 3B). In contrast, the anti-inflammatory
molecule IL-10 showed increased expression level in respon-
ders (P= 0⋅248) (Figure 3B).
Patients with VLU exhibit elevated mRNA levels of TAM
receptors and their ligands
We determined that elevated cytokine/chemokine levels and
microbial superinfection are a hallmark of VLU. We hypothe-
sised malfunctions in the negative regulation of innate immune
response and clearance of microbes and apoptotic cells in
diseased tissue. Thus, we sought to determine the expression
patterns of TAM receptors (Tyro3, Axl, MerTK) and their
ligands Gas6 and ProS in patients with VLU and control
probands. We determined marked increase in the expression
of all five mRNAs in VLU patients (Figure 4A). Interestingly,
when we compared the expression of the respective molecules
in responders versus non-responders, we identified Axl as sig-
nificantly upregulated and Gas6 as significantly downregulated
in responders (Figure 4B).
Discussion
In our study, we evaluated the expression of pro- and
anti-inflammatory cytokines/chemokines and the intrinsic
inhibitors of the inflammatory response, the TAM receptors
and their ligands (Gas6 and ProS) in probands with and without
VLU. To explore gene expression with more insight, we also
made a comparison within the VLU group on the basis of
responsiveness to appropriate wound care, and thus we were
able to discriminate between responder and non-responder
VLU patients.
Unlike normal wound healing, VLUs are trapped in
non-resolving, sustained inflammation (5,6,8,14) and
long-standing inflammation enhances the propensity for
intensive microbial colonisation. Conversely, infectious agents
amplify and even prolong the ongoing inflammatory process.
The current host condition influenced by age and nutritional
and metabolic status might be a real burden for efficient wound
healing (27). In addition, immune function plays a critical role
in the modulation of inflammation. Regulation might play a
central role in the agitation or silencing of immune mechanisms
and this area has deserved an increasing interest in recent times.
All chronic wounds contain microorganisms regardless of
whether they are clinically infected or not (5,28,29). To assess
the correlation between the presence of microorganisms and
VLU, we also analysed the microbiota spectrum of chronic
wounds. After wound dressing, removal bacterial swabs were
collected immediately. Instead of biopsy or other complicated
techniques, superficial swabs were carried out, as Gjødsbøl
et al. recently compared swab, biopsy and filter padding meth-
ods and reported that no differences were detected (30). Micro-
bial cultures showed the dominance of S. aureus and P. aerug-
inosa, which is in good concordance with a large comparative
study on leg ulcer colonising bacteria (31). The proportion of S.
aureus from therapy-resistant ulcers appeared to be markedly
lower in our study compared with the results of the latest
clinical investigation (39% versus 53%, respectively) whereas
P. aeruginosa represented nearly the same prevalence (22%
versus 25%, respectively). Our experimental setting clearly
showed that therapy-responder VLUs had a more balanced
microbial spectrum with 13% of Staphylococcus- and 16% of
Pseudomonas-positive cultures.
The different microbial colonisation patterns of responder
and non-responder chronic wounds might reflect the differ-
ent inflammatory cytokine responses. Microbes express a
wide range of virulence factors, which challenge macrophage
immune competence. Phagocytosis could be a crucial mech-
anism in S. aureus and P. aeruginosa clearance; however,
macrophages are capable of mounting an inflammatory
response eliciting strong production of IL-1α, TNFα and
CXCL-8 (32–35).
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A
B
Figure 3 Gene expression pattern of inﬂammatory chemokines/cytokines: venous leg ulcer (VLU) patients versus control probands (A) and VLU
non-responders versus VLU responders (B). The ratio of each mRNA is relative to 18S rRNA. Bars show means Warning: pl. change to entity± SEM.
*Signiﬁcantly different from each other as determined with one-way ANOVA following Neuman–Keuls post hoc test; P ≤0⋅05.
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A
B
Figure 4 Gene expression pattern of TAM (Tyro, Axl, MerTK) receptors and their ligands Gas6 and ProS: venous leg ulcer (VLU) patients versus control AQ7
probands (A) and VLU non-responder versus VLU responders (B). The ratio of eachmRNA is relative to 18S rRNA. Bars showmeansWarning: pl. change
to entity± SEM. *Signiﬁcantly different from each other as determined with one-way ANOVA following Neuman–Keuls post hoc test; P ≤0⋅05.
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One of the key features in non-healing wounds appeared to
be the constant stimulation of innate immune response (10) and
macrophages have a critical role throughout wound healing.
They have a polarised action: there is a pro-inflammatory subset
(M1) with inflammatory cytokine production and bactericidal
activity, and the other is an anti-inflammatory (immunomodu-
lator) (M2) subset linked with wound healing and tissue repair
processes. The initial phase requires effector function, followed
by tissue formation with VEGF and PDGF production, andAQ8
finally, the anti-inflammatory function should be predominant
with IL-1RA, IL-10 and TGF-β1 release (13). Taken these data
together, a switch from pro- to anti-inflammatory phenotype
with adequate timing might be beneficial by promoting wound
healing (10).
Because killing and phagocytic activities are reliable mea-
sures of innate immune function, we applied a simple method
to assess the killing activity of PBMCs isolated from VLU
patients. By using the power of in vitroC. albicans killing assay,
which serves as a standardmodel to quantify host response (23),
we determined that PBMCs from VLU patients do not harbour
gross perturbations in immune function.
Clinical studies in wound healing mostly focus on local
alterations of inflammatory cytokine expressions (9); how-
ever, a novel study found that infected wounds produced an
upregulation of circulating inflammatory cytokine pattern
compared with non-infected ones (8). This is one of the first
evidence to prove a remarkable influence of leg ulcers on
systemic immune response. The current results show that
circulating PMBCs of VLU patients robustly overexpress both
pro- and anti-inflammatory cytokines/chemokines compared
with those measured in control proband group. Importantly,
non-responder VLU patients show a notable upregulation of
IL-1α and CXCL-8 gene expression supporting the prolonged
pro-inflammatory status of their leg ulcers and the massive
Staphylococus and Pseudomonas colonisation (32–35). Lower
expression of pro-inflammatory effectors (IL-1α, CXCL-8
and TNFα) and higher, although statistically non-significant,
expression of anti-inflammatory cytokine IL-10 refer to the
silencing and clearance of inflammation in patients with better
wound healing prognosis.
TAM family of receptor tyrosine kinases – Tyro3, Axl,
MerTK – and their common ligand Gas6, among others, play
a central role in the intrinsic inhibition of the inflammatory
response to pathogens and regulate phagocytosis of apop-
totic cells (18). TAM receptor signaling – prominently through
MerTK – is required for the phagocytosis of apoptotic cells
by immune cells, such as macrophages and dendritic cells.
The majority of these cells express MerTK and Axl but
weakly Tyro3. In addition, Axl regulates and stimulates angio-
genesis, proliferation and cell migration. Circulating innate
immune cells of patients with septicaemia show increased
MerTK expression compared with those of healthy individu-
als or trauma patients. In contrast, Tyro3 and Axl expressions
were more pronounced in monocytes from trauma patients (21).
Interestingly, the final stage of inflammatory cycle is known to
involve TAM signalling (36): as a consequence of TAM acti-
vation, the TLR-driven pro-inflammatory cytokine/chemokine
secretion is markedly downregulated. Our recent study has
shown that their expression is also altered in psoriasis (37),
another pathophysiological condition with increased cytokine
expression. Hence, dysregulation of innate immune surveil-
lance could explain some features of prolonged inflammation
in chronic wound healing. Here, we show that both TAM recep-
tors and their ligands show elevated expression in VLU patients
as compared with control probands, indicative of the activ-
ity of the negative feedback regulation of the inflammation
and also reflecting the active phagocytic activity. Within VLU
patient group, responders show much higher Axl and signif-
icantly lower Gas6 gene expressions. High Axl activity may
explain the reduced rate of inflammation and the better response
to treatment option. Furthermore, Axl expression of PBMC is
strongly stimulated by inflammatory mediators of classical M1
activation. Simultaneously, a modest downregulation of Gas6
ligand gene could be detected (20). Our results are in close
agreement with the classical form of Axl upregulation and Gas6
downregulation, which serves the efficient inner control of tur-
bulent inflammatory response.
In fact, the exact mechanism and cooperation among TAM
tyrosine kinase family members and Gas6 and ProS ligands
remain to be elucidated; however this receptor tyrosine kinase
family and its ligands could presumably play a general role
in the comprehensive control of inflammation and, in turn, the
wound healing process.
To our knowledge, this is the first report where the expres-
sion pattern of TAM receptor family members and their ligands
was studied in chronic wound healing. Our approach is in good
concordance with an earlier editorial paper of International
Wound Journal, urging a more insightful focus on the unex-
plored immune mechanisms involved in chronic wound heal-
ing (38). Of note, IL-1α is robustly overexpressed in patients
remaining unresponsive to VLU treatment; in contrast, Axl
gene expression is dramatically upregulated among VLU car-
riers with sufficient healing properties. Hence, these markers
could be considered for facilitating the prediction of therapeuti-
cal response as a translation of our results into general practice.
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